WO2023237928 - IGF1R ANTIBODIES
National phase entry:
Publication Number
WO/2023/237928
Publication Date
14.12.2023
International Application No.
PCT/IB2023/000335
International Filing Date
08.06.2023
Title **
[English]
IGF1R ANTIBODIES
[French]
ANTICORPS ANTI-IGF1R
Applicants **
HORIZON THERAPEUTICS IRELAND DAC
Inventors
WARD, Christopher, Davidson
BORROK, III, Martin, Jack
Priority Data
63/351,077
10.06.2022
US
63/500,168
04.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2725 | |
| EPO | Filing, Examination, Granting | 17853 | |
| Japan | Filing, Examination, Granting | 2766 | |
| South Korea | Filing, Examination, Granting | 3105 | |
| USA | Filing, Examination, Granting | 7940 |
Total:
34,389
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Described herein are antibodies that bind and inhibit signaling through the insulin-like growth factor receptor 1.[French]
La présente invention concerne des anticorps qui se lient et inhibent la signalisation par l'intermédiaire du récepteur du facteur de croissance analogue à l'insuline de type 1.